JWC COVENANT INC P.O. Box 132919 The Woodlands, TX 77393 USA 1.281.364.7387 Fax 1.281.292.4378 www.hm2010.org
l
l
l
l
l
Continuing Medical Education
Educational Objectives
After attending the conference, participants should be able to:
- Interpret the biology of various hematologic malignancies that provide
rationales for choosing appropriate treatment strategies;
- Incorporate current treatment and monitoring strategies for patients with
newly diagnosed hematologic malignancies, thus leading to enhanced outcomes;
- Discuss issues surrounding the design and conduct of clinical trials that incorporate
novel agents and/or regimens for patients with rare malignancies;
- Assess the safety and efficacy of recent clinical advances in the management
of patients with hematologic malignancies;
- Evaluate difficult or unusual problems encountered by the practicing
hematologist/oncologist and implement appropriate interventional techniques
that will lead to better quality care;
- Utilize the latest management approaches to hematologic malignancies including
leukemia, lymphoma, multiple myeloma, MDS, MPDs and cancer-related
infectious disease that will result in improved patient outcomes.
Target Audience
This program is directed toward physicians interested in Hematology-Oncology,
Medical Oncology and Internal Medicine.
Educational Methods
Lectures, Question-and-Answer Sessions, Meet the Professor Sessions, Panel Discussions,
Posters Sessions, Other
Evaluation
A course evaluation form will provide participants with the opportunity to comment
on the value of the program content to their practice decisions, performance
improvement activities, or possible impact on patient health status. Participants
will also have the opportunity to comment on any perceived commercial bias
in the presentations as well as to identify future educational topics.
Accreditation/Credit Designation
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this educational activity for a maximum of 27.50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
CME Certificates and Attendance Verification Certificates
Certificates awarding AMA/PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.
Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.
The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.
Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.
Photographing, audiotaping or videotaping is prohibited.
The University of Texas M. D. Anderson Cancer Center is one of the nation's original three comprehensive cancer centers. It is both an academic institution and a cancer treatment/res-earch center. For 6 of the past eight years, M. D. Anderson has ranked No. 1 in cancer care in the "America's Best Hospitals" survey published in U.S. News & World Report.
